Novo’s actions held up 20% on Tuesday after the company called a new CEO and drop their waiting of their weight
In a statement on Tuesday, Northo Northisk she said Wait for his sales for 2025 to grow 8% -14%, down from the releases 13% -21% in May. If you have moved their expectations to operate profit growth until 10% -16%, up to 16% -24% in May.
The offer updated “reflections the persistent use of market expanding the compound, the most circle market competition,” The company said. GLUNCH-Likes Pepthide-1 Agonists (glp-1s), a class of used drugs to handle diabetes, they have up to date the weight loss industry.
Danish Pharmactic Company also announced Tuesday Appointment of Doustar Mossi Mike as President and Ceeya. Doustdarwho worked in Novonalized Numnarchio for more than 30 years, it has to fury starting from August 7.
Duoustdar successful WITHOUT FROGENANAN, which announced Novo sweat in May, who has left a hard price
Reached for comments, to 1 Northwest Rooks said they didn’t have something adoptial before the call of the company’s earnings, which is planned for the mercury, ag. ..
Copycat drugs pervade market
While whegovy’s global sales, the sales of weight weight drug are expected to weaken in some markets for increased competition by Composed versions of the drug.
The compound weight drugs have the same ingredients active as the other popular brands as ozempic, and are used as substitutes when drugs are not available. However, the food administration and drug (FDA) in April said there is no more than the lack of glp-1s and ordered COMPOSED Pharmacies to stop selling their copycat versions of popular loss drugs.
In spite efforts To stompate them, however, common versions of drugs continue to penetle in the name of the name of name of name as Wegovy, who can cost more than $ 1000 by package for those without insurance.
To Jugno, Novo Nordic ended his co-worker With hims & hers health on the claims that the rental drug retailer was sales to wegovy, a mobile novelis she said “Put the patient’s safety to the risk.”
CBS News School Contributor D Dr. GOUNDER CEINE he told the news of CBS The year the year that is not very supported on the consposed drug market, and that there is a wide range when it comes to the quality and risk associated with each drug.
Novo Northisk said Multiple Multiple to “Protect Patients from the” Knockoff “semaglitide” semagrutide drugs “including litigation. Semaglutide is the Ingredient active found in wegovy and ozempic.
“Novo NORCH is very concerned that, without aggressive intervention from federal regulators, continue to be bulk of semagic income statement. I am
contributed to this report.